JP2009538870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538870A5 JP2009538870A5 JP2009512572A JP2009512572A JP2009538870A5 JP 2009538870 A5 JP2009538870 A5 JP 2009538870A5 JP 2009512572 A JP2009512572 A JP 2009512572A JP 2009512572 A JP2009512572 A JP 2009512572A JP 2009538870 A5 JP2009538870 A5 JP 2009538870A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pain
- disease
- syndrome
- diaza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- -1 1,4-diaza-bicyclo [3.2.2] nonylpyrimidinyl Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020651 Hyperkinesia Diseases 0.000 claims 1
- 208000000269 Hyperkinesis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041247 Social fear Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 201000009863 inflammatory diarrhea Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- KFKFYOVMLCPCMT-UHFFFAOYSA-N n-[2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyrimidin-5-yl]-2-fluorobenzamide Chemical compound FC1=CC=CC=C1C(=O)NC1=CN=C(N2C3CCN(CC3)CC2)N=C1 KFKFYOVMLCPCMT-UHFFFAOYSA-N 0.000 claims 1
- OMGLTFYSOBZDLM-UHFFFAOYSA-N n-[2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyrimidin-5-yl]-2-fluorobenzamide;hydrochloride Chemical compound Cl.FC1=CC=CC=C1C(=O)NC1=CN=C(N2C3CCN(CC3)CC2)N=C1 OMGLTFYSOBZDLM-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Claims (5)
- N−[2−(1,4−ジアザ−ビシクロ[3.2.2]ノン−4−イル)−ピリミジン−5−イル]−2−フルオロ−ベンズアミド、又は薬学的に許容されるその塩である1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体。
- N−[2−(1,4−ジアザ−ビシクロ[3.2.2]ノン−4−イル)−ピリミジン−5−イル]−2−フルオロ−ベンズアミド塩酸塩である、請求項1に記載の1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体。
- 請求項1又は2に記載の1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体、又は薬学的に許容されるその付加塩、又はそのプロドラッグの治療有効量を、少なくとも1種の薬学的に許容される担体又は希釈剤と一緒に含む医薬組成物。
- ヒトを含む哺乳動物の疾患又は障害又は状態の治療、予防又は緩和用の医薬であって、請求項1又は2に記載の1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体、又は薬学的に許容されるその付加塩を含み、この疾患、障害又は状態は、コリン作動性受容体の調節に応答するものである、上記医薬。
- 疾患、障害又は状態が、認識力障害、学習障害、記憶障害及び機能不全、ダウン症候群、アルツハイマー病、注意欠陥、注意欠陥過活動性障害(ADHD)、トゥーレット症候群、精神病、うつ病、双極性障害、躁病、躁うつ病、統合失調症、統合失調症に関係した認知障害又は注意欠陥、強迫性障害(OCD)、パニック障害、拒食症、過食症及び肥満などの摂食障害、ナルコレプシー、侵害受容、AIDS認知症、老年性認知症、自閉症、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、不安、非OCD不安障害、けいれん性障害、てんかん、神経変性障害、一過性無酸素症、誘発性神経変性、ニューロパシー、糖尿病性ニューロパシー、末梢性失読症、遅発性ジスキネジー、運動過剰症、軽度の痛み、中等度の又は激しい痛み、急性の、慢性の又は反復性の痛み、片頭痛に起因する痛み、術後疼痛、幻肢痛、炎症性疼痛、神経因性疼痛、慢性頭痛、中心性疼痛、糖尿病性ニューロパシー、ヘルペス後神経痛、又は末梢神経損傷に関係する痛み、過食症、外傷後症候群、対人恐怖、睡眠障害、偽認知症、ガンゼル症候群、月経前症候群、後期黄体期症候群、線維筋痛、慢性疲労症候群、無言症、抜毛癖、時差ぼけ、不整脈、平滑筋収縮、狭心症、早期分娩、下痢、ぜんそく、遅発性ジスキネジー、運動過剰症、早漏、勃起不全、高血圧、炎症性疾患、炎症性皮膚障害、座瘡、酒さ、クローン病、炎症性大腸炎、潰瘍性大腸炎、下痢、又はタバコなどのニコチン含有製品、ヘロイン、コカイン及びモルヒネなどのオピオイド、ベンゾジアゼピン及びベンゾジアゼピン様薬物、及びアルコールを含む中毒性物質の使用の停止に起因する禁断症状である、請求項4に記載の医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80902306P | 2006-05-30 | 2006-05-30 | |
DKPA200600730 | 2006-05-30 | ||
PCT/EP2007/055172 WO2007138041A1 (en) | 2006-05-30 | 2007-05-29 | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009538870A JP2009538870A (ja) | 2009-11-12 |
JP2009538870A5 true JP2009538870A5 (ja) | 2010-05-27 |
Family
ID=38258823
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009512572A Abandoned JP2009538870A (ja) | 2006-05-30 | 2007-05-29 | 新規な1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体及びその医学的使用 |
JP2009512571A Abandoned JP2009538869A (ja) | 2006-05-30 | 2007-05-29 | 新規な1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体及びその医学的使用 |
JP2009512570A Abandoned JP2009538868A (ja) | 2006-05-30 | 2007-05-29 | 新規な1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体及びその医学的使用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009512571A Abandoned JP2009538869A (ja) | 2006-05-30 | 2007-05-29 | 新規な1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体及びその医学的使用 |
JP2009512570A Abandoned JP2009538868A (ja) | 2006-05-30 | 2007-05-29 | 新規な1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジニル誘導体及びその医学的使用 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20090197872A1 (ja) |
EP (3) | EP2041134A1 (ja) |
JP (3) | JP2009538870A (ja) |
AU (3) | AU2007267178A1 (ja) |
CA (3) | CA2653371A1 (ja) |
MX (3) | MX2008014889A (ja) |
WO (3) | WO2007138040A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005074940A1 (en) * | 2004-02-04 | 2005-08-18 | Neurosearch A/S | Diazabicyclic aryl derivatives as cholinergic receptor modulators |
CA2653371A1 (en) * | 2006-05-30 | 2007-12-06 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use |
US7935695B2 (en) | 2007-08-17 | 2011-05-03 | Neurosearch A/S | 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands |
DE102007053771A1 (de) * | 2007-11-12 | 2009-05-14 | Merck Patent Gmbh | Organische Elektrolumineszenzvorrichtungen |
JP2011503145A (ja) * | 2007-11-14 | 2011-01-27 | ノイロサーチ アクティーゼルスカブ | 新規な1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジン誘導体及びその医学的使用 |
JP2011503144A (ja) * | 2007-11-14 | 2011-01-27 | ノイロサーチ アクティーゼルスカブ | 新規の1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジン誘導体及びその医療への使用 |
JP2011503146A (ja) * | 2007-11-14 | 2011-01-27 | ノイロサーチ アクティーゼルスカブ | 新規な1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジン誘導体及びこれらの医療上の使用 |
WO2010026176A1 (en) * | 2008-09-05 | 2010-03-11 | Neurosearch A/S | 1,4 -diaza- bicyclo [3.2.2]n0nyl pyrimidine derivatives as nicotinic and monoamine receptor modulators |
WO2010026177A1 (en) * | 2008-09-05 | 2010-03-11 | Neurosearch A/S | 1,4-diaza-bicyclo [3.2.2] nonyl pyridine derivatives as nicotinic and monoamine receptor modulators |
US20110269778A1 (en) * | 2008-10-10 | 2011-11-03 | Neurosearch A/S | Novel diphenyl purine derivatives useful as modulators of nicotinic acetylcholine receptors |
US20110257161A1 (en) * | 2008-12-04 | 2011-10-20 | Neurosearch A/S | Novel diaza-bicyclononyl-phenyl derivatives and their medical use |
WO2010084120A1 (en) * | 2009-01-21 | 2010-07-29 | Neurosearch A/S | N-oxides of 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine receptor ligands |
US20120028967A1 (en) * | 2009-01-21 | 2012-02-02 | Neurosearch A/S | Novel diaza-bicyclononyl-pyrimidinyl derivatives and their medical use |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2786770B1 (fr) | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
CA2433772C (en) * | 2001-02-14 | 2008-10-07 | Warner-Lambert Company Llc | Pyrimidine matrix metalloproteinase inhibitors |
BR0210391A (pt) * | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
JP2006504690A (ja) | 2002-09-10 | 2006-02-09 | ファイザー・プロダクツ・インク | Cns及びその他の障害の治療に有用なジアザ二環式化合物 |
PL375025A1 (en) | 2002-09-30 | 2005-11-14 | Neurosearch A/S | Novel 1,4-diazabicycloalkane derivatives, their preparation and use |
US7223753B2 (en) | 2002-11-11 | 2007-05-29 | Neurosearch A/S | Diazabicyclic biaryl derivatives |
WO2004043960A1 (en) | 2002-11-11 | 2004-05-27 | Neurosearch A/S | 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof |
BRPI0506881A (pt) | 2004-02-04 | 2007-06-26 | Neurosearch As | derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo |
WO2005074940A1 (en) * | 2004-02-04 | 2005-08-18 | Neurosearch A/S | Diazabicyclic aryl derivatives as cholinergic receptor modulators |
WO2006087306A2 (en) | 2005-02-16 | 2006-08-24 | Neurosearch A/S | Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors |
CA2653371A1 (en) | 2006-05-30 | 2007-12-06 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use |
US7935695B2 (en) | 2007-08-17 | 2011-05-03 | Neurosearch A/S | 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands |
CA2696680A1 (en) | 2007-08-17 | 2009-02-26 | Neurosearch A/S | 1,4-diaza-bicycl0(3.2.2)n0nyl pyrimidinyl derivatives useful as nicotinic acetylcholine- receptor ligands |
JP2011503146A (ja) * | 2007-11-14 | 2011-01-27 | ノイロサーチ アクティーゼルスカブ | 新規な1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジン誘導体及びこれらの医療上の使用 |
JP2011503144A (ja) * | 2007-11-14 | 2011-01-27 | ノイロサーチ アクティーゼルスカブ | 新規の1,4−ジアザ−ビシクロ[3.2.2]ノニルピリミジン誘導体及びその医療への使用 |
-
2007
- 2007-05-29 CA CA002653371A patent/CA2653371A1/en not_active Abandoned
- 2007-05-29 CA CA002653681A patent/CA2653681A1/en not_active Abandoned
- 2007-05-29 JP JP2009512572A patent/JP2009538870A/ja not_active Abandoned
- 2007-05-29 EP EP07729592A patent/EP2041134A1/en not_active Withdrawn
- 2007-05-29 US US12/299,108 patent/US20090197872A1/en not_active Abandoned
- 2007-05-29 WO PCT/EP2007/055171 patent/WO2007138040A1/en active Application Filing
- 2007-05-29 JP JP2009512571A patent/JP2009538869A/ja not_active Abandoned
- 2007-05-29 AU AU2007267178A patent/AU2007267178A1/en not_active Abandoned
- 2007-05-29 WO PCT/EP2007/055172 patent/WO2007138041A1/en active Application Filing
- 2007-05-29 US US12/299,114 patent/US7915272B2/en not_active Expired - Fee Related
- 2007-05-29 US US12/299,106 patent/US8148365B2/en not_active Expired - Fee Related
- 2007-05-29 JP JP2009512570A patent/JP2009538868A/ja not_active Abandoned
- 2007-05-29 EP EP07729594A patent/EP2029595B1/en not_active Not-in-force
- 2007-05-29 MX MX2008014889A patent/MX2008014889A/es not_active Application Discontinuation
- 2007-05-29 EP EP07729593A patent/EP2049538A1/en not_active Withdrawn
- 2007-05-29 MX MX2008014890A patent/MX2008014890A/es not_active Application Discontinuation
- 2007-05-29 MX MX2008014885A patent/MX2008014885A/es not_active Application Discontinuation
- 2007-05-29 AU AU2007267176A patent/AU2007267176A1/en not_active Abandoned
- 2007-05-29 CA CA002653460A patent/CA2653460A1/en not_active Abandoned
- 2007-05-29 WO PCT/EP2007/055170 patent/WO2007138039A1/en active Application Filing
- 2007-05-29 AU AU2007267177A patent/AU2007267177A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009538870A5 (ja) | ||
JP2009538869A5 (ja) | ||
JP2009538867A5 (ja) | ||
JP2009526814A5 (ja) | ||
JP2008530171A5 (ja) | ||
JP2009537599A5 (ja) | ||
JP2007520525A5 (ja) | ||
JP2009538866A5 (ja) | ||
JP2007530635A5 (ja) | ||
RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
JP2005538187A5 (ja) | ||
JP2008530172A5 (ja) | ||
WO2006019886A3 (en) | Pyrrolo(oxo)isoquinolines as 5ht ligands | |
IL215910A (en) | Derivatives 4,2,1 - Triazolo [3,4 – a] Pyridine, pharmaceutical preparations contain them and processes for their preparation and their uses for the preparation of drugs for the treatment of diseases of the central nervous system | |
WO2007084450A3 (en) | Cannibinoid receptor modulators | |
WO2010046445A3 (en) | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | |
BRPI0511344A (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto combinado | |
WO2008117269A3 (en) | Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof | |
JP2008517032A5 (ja) | ||
JP2007538046A5 (ja) | ||
JP2009526776A5 (ja) | ||
JP2008526706A5 (ja) | ||
WO2007138040A8 (en) | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use | |
JP2012508275A5 (ja) | ||
WO2008153937A3 (en) | Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |